Skip to content

An Assessment of P-15 Bone Putty in Anterior Cervical Fusion With Instrumentation

An Assessment of P-15 Bone Putty in Anterior Cervical Fusion With Instrumentation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00310440
Enrollment
319
Registered
2006-04-04
Start date
2006-01-31
Completion date
2019-05-23
Last updated
2020-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intervertebral Disk Degeneration

Keywords

Degenerative disc disease, P-15 Bone Putty, Bone graft, Cervical discectomy, Cervical spine

Brief summary

The aim of this trial is to evaluate if P-15 bone putty (investigational device) is not inferior in effectiveness and safety to local autologous bone (control device) when applied in instrumented anterior cervical discectomy and fusion (ACDF) with use of a structural allograft ring in patients with degenerative cervical disc disease..

Detailed description

Anterior Cervical Discectomy and Fusion (ACDF) is a common surgical treatment option for symptomatic degenerative cervical disk disease in patients who fail conservative treatment. i-FACTOR bone graft is a unique anorganic bone mineral (ABM) and small peptide, P-15™. P-15 is a synthetic fifteen amino acid polypeptide that mimics the cell-binding domain of Type I human collagen and is responsible for osteogenic cell attachment via alpha2-beta1 integrins. This is randomized, controlled, multi-center, prospective FDA IDE study conducted to assess the safety and effectiveness of i-FACTOR bone graft (Cerapedics, Inc. Westminster, CO) in patients treated with single level ACDF. Patients received i-FACTOR bone graft or local autologous bone inside a structural allograft.

Interventions

DEVICEP-15 Synthetic osteoconductive bone substitute

Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery

OTHERAutologous bone

Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring

Sponsors

CeraPedics, Inc
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Age between 18 and 65 * Radiographically determined discogenic origin to include at least one of the following characteristics: degenerated/dark disc on MRI, decreased disc height compared to adjacent levels on radiographic film, CT, or MRI and disc herniation on CT or MRI * Radicular symptoms by history and physical exam to include at least the following characteristics: Arm/shoulder pain, decreased flexes, decreased strength and abnormal sensation * Pain level arm/shoulder \>4 on 0-10 VAS * Pain level neck \>4 on 0-10 VAS * Neck disability Index \>30 * Involved discs between C3 and C7 * Undergoing anterior cervical fusion at a single level * Failed to gain adequate relief from non-operative treatment * Able and willing to give consent to participate in study * Understand and read English at elementary level

Exclusion criteria

Systemic infection such as AIDS, HIV, and active hepatitis; Significant metabolic disease that in the surgeon's opinion might compromise bone growth such as osteoporosis or osteomalacia; Taking medication for the prevention of osteoporosis; Circulatory, cardiac, or pulmonary problems that could cause excessive surgical risk; Active malignancy; Nondiscogenic source of symptoms (e.g., tumor, etc.); Multiple level symptomatic degenerative disc disease; Previous cervical fusion; Previous cervical decompression at the same level; Acute cervical trauma or instability (i.e., subluxation \> 3 mm on flexion/extension radiographic film); Undergoing treatment for tumor or bony traumatic injury to the cervical spine; Rheumatoid disease of the cervical spine; Myelopathy; Pregnant or planning to become pregnant in the next 2 years; Posterior cervical spine procedure scheduled; More than one level to be operated; Has a history of substance abuse (recreational drugs, alcohol); Is a prisoner; Is currently involved in a study of another investigational product for similar purpose; Has a disease process that would preclude accurate evaluation (e.g., neuromuscular disease, significant psychiatric disease).

Design outcomes

Primary

MeasureTime frameDescription
Radiologic Fusion12 monthsSuccessful fusion was based on roentgenographic examination showing: evidence of bridging trabecular bone between the involved motion segments, translational motion \<3mm, and angular motion \<5 degrees. If there was a lack of evidence of fusion on 12 month plain x-ray examination, a CT-scan was performed and final determination of the fusion status was made using the CT reading. The criteria for fusion on CT scans were: trabecular bone formation patterns within the intervertebral disc space and bridging bone formation that crosses the interspace.
Change in of the Overall Neck Disability Index (NDI) Score From Baseline.12 monthsThe NDI consists of ten items addressing functional activities (personal care, lifting, reading, work, driving, sleeping, recreational activities), pain intensity, concentration and headache. For each item, there are six potential responses, describing increasing degrees of disability (no disability = 0 to total disability = 5). An overall NDI score, out of 100, is calculated by adding up the scores for each item and multiplying by two. A higher NDI score indicates greater disability.
Neurologic Success12 monthsThe neurological endpoint is a binary variable. Neurologic success was assessed in the motor, sensory and reflex domains specific for the cervical spine as follows: maintenance or improvement of motor function in the elbow flexors (i.e. biceps muscle), elbow extensors (i.e. triceps muscle) and wrist extensors of both arms; maintenance or improvement of sensory function of both arms; maintenance or improvement of reflexes of both arms as measured at biceps tendon, triceps tendon and brachioradialis (supinator) reflex AND absence of Babinski reflex (if not present prior to surgery). Worsening of neurological status (neurological failure) was defined as a permanent decline in the subject's neurological status based on adjudication of accumulated neurological data by an independent blinded evaluator.
Complications12 monthsAny AE within 12 months of surgery.

Secondary

MeasureTime frameDescription
Mean Change in the Short Form 36 v2 (SF-36v2) Mental Health Composite Score (MCS).Baseline and 12 monthsThe SF-36 v2 (Medical Outcomes Trust, Boston, MA) is a multipurpose, patient-reported short-form health survey with 36 questions available in several languages. It yields two composite scores: one for physical health (Physical Composite Score - PCS) and one for mental health (Mental Composite Score - MCS) that are comprised of eight domains. The following domains make up the MCS: vitality, social functioning, role-emotional, mental health. The MCS ranges from a score of 0 (lowest possible level of functioning) to a score of 100 (highest possible level of functioning).
Mean Change in Pain at Neck Visual Analog Scale (VAS).Baseline and 12 monthsThe pain VAS is a continuous scale upon which the subject indicates their pain level ranging from No pain at all (0) to Worst imaginable pain (10). The change in pain is calculated by subtracting the 12 month score from the baseline score.
Kyphosis12 monthsKyphosis is evaluated in degrees.
Mean Change at Pain at Arm and Shoulder Visual Analog Scale (VAS).Baseline and 12 monthsThe pain VAS is a continuous scale upon which the subject indicates their pain level ranging from No pain at all (0) to Worst imaginable pain (10). The change in pain is calculated by subtracting the 12 month score from the baseline score.
Success Rates Measured by Aggregated Modified Odom's Criteria12 monthsSubjects selected one of four categories: Excellent (Improvement Greater than or Equal to 80%, Deterioration Less than 10%), Good (Improvement Greater than or Equal to 70%, Deterioration Less than 15%), Fair (Improvement Greater than or Equal to 50%, Deterioration Less than 20%) or Poor (Improvement Less than 50%, Deterioration Greater than 20%).
Mean Change in the Short Form 36 v2 (SF-36v2) Physical Composite Score (PCS).Baseline and 12 monthsThe SF-36 v2 (Medical Outcomes Trust, Boston, MA) is a multipurpose, patient-reported short-form health survey with 36 questions available in several languages. It yields two composite scores: one for physical health (Physical Composite Score - PCS) and one for mental health (Mental Composite Score - MCS) that are comprised of eight domains. The following domains make up the PCS: physical functioning, role-physical, bodily pain, general health. The PCS ranges from a score of 0 (lowest possible level of functioning) to a score of 100 (highest possible level of functioning).

Countries

Canada, United States

Participant flow

Participants by arm

ArmCount
Bone Graft Substitute
Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with P-15 synthetic osteoconductive bone substitute (investigational device). P-15 Synthetic osteoconductive bone substitute: Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery
165
Autologous Bone
Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with local autologous bone. Autologous bone: Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring
154
Total319

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up178
Overall StudyMissed 12 Month Visit74
Overall StudyWithdrawal by Subject21

Baseline characteristics

CharacteristicBone Graft SubstituteTotalAutologous Bone
Age, Continuous47.7 years
STANDARD_DEVIATION 9.7
46.8 years
STANDARD_DEVIATION 9.6
45.7 years
STANDARD_DEVIATION 9.4
Ethnicity (NIH/OMB)
Hispanic or Latino
7 Participants11 Participants4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
157 Participants307 Participants150 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants1 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants1 Participants0 Participants
Race (NIH/OMB)
Asian
4 Participants5 Participants1 Participants
Race (NIH/OMB)
Black or African American
5 Participants11 Participants6 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants7 Participants3 Participants
Race (NIH/OMB)
White
151 Participants295 Participants144 Participants
Region of Enrollment
Canada
29 participants55 participants26 participants
Region of Enrollment
United States
136 participants264 participants128 participants
Sex: Female, Male
Female
95 Participants192 Participants97 Participants
Sex: Female, Male
Male
70 Participants127 Participants57 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
136 / 165128 / 154
serious
Total, serious adverse events
45 / 16535 / 154

Outcome results

Primary

Change in of the Overall Neck Disability Index (NDI) Score From Baseline.

The NDI consists of ten items addressing functional activities (personal care, lifting, reading, work, driving, sleeping, recreational activities), pain intensity, concentration and headache. For each item, there are six potential responses, describing increasing degrees of disability (no disability = 0 to total disability = 5). An overall NDI score, out of 100, is calculated by adding up the scores for each item and multiplying by two. A higher NDI score indicates greater disability.

Time frame: 12 months

Population: Per protocol (PP) subjects were included in this analysis. Six subjects that had major protocol deviations with the potential to impact the primary endpoint results were not included in the PP population.

ArmMeasureValue (LEAST_SQUARES_MEAN)
Bone Graft SubstituteChange in of the Overall Neck Disability Index (NDI) Score From Baseline.28.75 units on a scale
Autologous BoneChange in of the Overall Neck Disability Index (NDI) Score From Baseline.27.40 units on a scale
Primary

Complications

Any AE within 12 months of surgery.

Time frame: 12 months

Population: All enrolled subjects.

ArmMeasureGroupValue (NUMBER)
Bone Graft SubstituteComplicationsYes138 participants
Bone Graft SubstituteComplicationsNo27 participants
Autologous BoneComplicationsYes127 participants
Autologous BoneComplicationsNo27 participants
Primary

Neurologic Success

The neurological endpoint is a binary variable. Neurologic success was assessed in the motor, sensory and reflex domains specific for the cervical spine as follows: maintenance or improvement of motor function in the elbow flexors (i.e. biceps muscle), elbow extensors (i.e. triceps muscle) and wrist extensors of both arms; maintenance or improvement of sensory function of both arms; maintenance or improvement of reflexes of both arms as measured at biceps tendon, triceps tendon and brachioradialis (supinator) reflex AND absence of Babinski reflex (if not present prior to surgery). Worsening of neurological status (neurological failure) was defined as a permanent decline in the subject's neurological status based on adjudication of accumulated neurological data by an independent blinded evaluator.

Time frame: 12 months

Population: The total number of observed subjects.

ArmMeasureGroupValue (NUMBER)
Bone Graft SubstituteNeurologic SuccessYes134 participants
Bone Graft SubstituteNeurologic SuccessNo9 participants
Autologous BoneNeurologic SuccessYes133 participants
Autologous BoneNeurologic SuccessNo10 participants
Primary

Radiologic Fusion

Successful fusion was based on roentgenographic examination showing: evidence of bridging trabecular bone between the involved motion segments, translational motion \<3mm, and angular motion \<5 degrees. If there was a lack of evidence of fusion on 12 month plain x-ray examination, a CT-scan was performed and final determination of the fusion status was made using the CT reading. The criteria for fusion on CT scans were: trabecular bone formation patterns within the intervertebral disc space and bridging bone formation that crosses the interspace.

Time frame: 12 months

Population: All participants that have radiological data at 12 months including imputed data.

ArmMeasureGroupValue (NUMBER)
Bone Graft SubstituteRadiologic FusionFused129 participants
Bone Graft SubstituteRadiologic FusionNo Evidence of Fusion16 participants
Autologous BoneRadiologic FusionFused121 participants
Autologous BoneRadiologic FusionNo Evidence of Fusion20 participants
Secondary

Kyphosis

Kyphosis is evaluated in degrees.

Time frame: 12 months

Population: Per protocol (PP) subjects who had images available at 12 months were included in this analysis. Six subjects that had major protocol deviations with the potential to impact the primary endpoint results were not included in the PP population.

ArmMeasureValue (MEAN)Dispersion
Bone Graft SubstituteKyphosis3.0 degreesStandard Deviation 5
Autologous BoneKyphosis3.8 degreesStandard Deviation 4.9
Secondary

Mean Change at Pain at Arm and Shoulder Visual Analog Scale (VAS).

The pain VAS is a continuous scale upon which the subject indicates their pain level ranging from No pain at all (0) to Worst imaginable pain (10). The change in pain is calculated by subtracting the 12 month score from the baseline score.

Time frame: Baseline and 12 months

Population: Per protocol (PP) subjects were included in this analysis. Six subjects that had major protocol deviations with the potential to impact the primary endpoint results were not included in the PP population.

ArmMeasureValue (MEAN)
Bone Graft SubstituteMean Change at Pain at Arm and Shoulder Visual Analog Scale (VAS).4.89 cm
Autologous BoneMean Change at Pain at Arm and Shoulder Visual Analog Scale (VAS).4.85 cm
Secondary

Mean Change in Pain at Neck Visual Analog Scale (VAS).

The pain VAS is a continuous scale upon which the subject indicates their pain level ranging from No pain at all (0) to Worst imaginable pain (10). The change in pain is calculated by subtracting the 12 month score from the baseline score.

Time frame: Baseline and 12 months

Population: Per protocol (PP) subjects were included in this analysis. Six subjects that had major protocol deviations with the potential to impact the primary endpoint results were not included in the PP population.

ArmMeasureValue (MEAN)
Bone Graft SubstituteMean Change in Pain at Neck Visual Analog Scale (VAS).4.45 cm
Autologous BoneMean Change in Pain at Neck Visual Analog Scale (VAS).4.39 cm
Secondary

Mean Change in the Short Form 36 v2 (SF-36v2) Mental Health Composite Score (MCS).

The SF-36 v2 (Medical Outcomes Trust, Boston, MA) is a multipurpose, patient-reported short-form health survey with 36 questions available in several languages. It yields two composite scores: one for physical health (Physical Composite Score - PCS) and one for mental health (Mental Composite Score - MCS) that are comprised of eight domains. The following domains make up the MCS: vitality, social functioning, role-emotional, mental health. The MCS ranges from a score of 0 (lowest possible level of functioning) to a score of 100 (highest possible level of functioning).

Time frame: Baseline and 12 months

Population: Per protocol (PP) subjects were included in this analysis. Six subjects that had major protocol deviations with the potential to impact the primary endpoint results were not included in the PP population.

ArmMeasureValue (LEAST_SQUARES_MEAN)
Bone Graft SubstituteMean Change in the Short Form 36 v2 (SF-36v2) Mental Health Composite Score (MCS).8.33 score on a scale
Autologous BoneMean Change in the Short Form 36 v2 (SF-36v2) Mental Health Composite Score (MCS).8.21 score on a scale
Secondary

Mean Change in the Short Form 36 v2 (SF-36v2) Physical Composite Score (PCS).

The SF-36 v2 (Medical Outcomes Trust, Boston, MA) is a multipurpose, patient-reported short-form health survey with 36 questions available in several languages. It yields two composite scores: one for physical health (Physical Composite Score - PCS) and one for mental health (Mental Composite Score - MCS) that are comprised of eight domains. The following domains make up the PCS: physical functioning, role-physical, bodily pain, general health. The PCS ranges from a score of 0 (lowest possible level of functioning) to a score of 100 (highest possible level of functioning).

Time frame: Baseline and 12 months

Population: Per protocol (PP) subjects were included in this analysis. Six subjects that had major protocol deviations with the potential to impact the primary endpoint results were not included in the PP population.

ArmMeasureValue (LEAST_SQUARES_MEAN)
Bone Graft SubstituteMean Change in the Short Form 36 v2 (SF-36v2) Physical Composite Score (PCS).10.02 units on a scale
Autologous BoneMean Change in the Short Form 36 v2 (SF-36v2) Physical Composite Score (PCS).9.95 units on a scale
Secondary

Success Rates Measured by Aggregated Modified Odom's Criteria

Subjects selected one of four categories: Excellent (Improvement Greater than or Equal to 80%, Deterioration Less than 10%), Good (Improvement Greater than or Equal to 70%, Deterioration Less than 15%), Fair (Improvement Greater than or Equal to 50%, Deterioration Less than 20%) or Poor (Improvement Less than 50%, Deterioration Greater than 20%).

Time frame: 12 months

Population: Per protocol (PP) subjects that had data available at the 12 month visit were included in this analysis. Six subjects that had major protocol deviations with the potential to impact the primary endpoint results were not included in the PP population.

ArmMeasureGroupValue (NUMBER)
Bone Graft SubstituteSuccess Rates Measured by Aggregated Modified Odom's CriteriaExcellent: Improvement GE 80% Deterioration LT 10%80 participants
Bone Graft SubstituteSuccess Rates Measured by Aggregated Modified Odom's CriteriaGood: Improvement GE 70% Deterioration LT 15%25 participants
Bone Graft SubstituteSuccess Rates Measured by Aggregated Modified Odom's CriteriaFair: Improvement GE 50% Deterioration LT 20%16 participants
Bone Graft SubstituteSuccess Rates Measured by Aggregated Modified Odom's CriteriaPoor: Improvement LT 50% Deterioration GT 20%8 participants
Autologous BoneSuccess Rates Measured by Aggregated Modified Odom's CriteriaPoor: Improvement LT 50% Deterioration GT 20%9 participants
Autologous BoneSuccess Rates Measured by Aggregated Modified Odom's CriteriaExcellent: Improvement GE 80% Deterioration LT 10%80 participants
Autologous BoneSuccess Rates Measured by Aggregated Modified Odom's CriteriaFair: Improvement GE 50% Deterioration LT 20%15 participants
Autologous BoneSuccess Rates Measured by Aggregated Modified Odom's CriteriaGood: Improvement GE 70% Deterioration LT 15%25 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026